July 1, 2021 05:02 PM EDT

Sirnaomics puts off an IPO a little longer as it pockets another megaround. Is an S-1 around the corner this time?

Nicole DeFeudis

Editor

Back in October, when small interfering RNA player Sirnaomics landed its Series D round, CEO Patrick Lu said he was open to preparing for …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER

ENDPOINTS CAREERS

‭ Regulatory Lead / Head of Regulatory‬

Autonomy Bio Inc.

San Francisco, CA 94107, USA

view job offer post your job now

TRENDING NOW

HHS says it's pulled Covid shot guidance for healthy kids. The CDC vaccine schedule shows otherwise

Updated: Patient dies in Rocket gene therapy trial, which is put on clinical hold by FDA

Lilly to buy non-opioid pain biotech SiteOne for up to $1B

Vertex touts promising first few months of launch for non-opioid pain drug Journavx

Vertex's next challenge for pain pill? Cracking a market dominated by cheap opioids

sponsored

From weeks to days: how Aizon Intelligent Agents transform pharma validation